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Editorial
Today, genomics research, supported by protein expres-
sion studies, pave the way for the progress within molec-
ular medicine. These developments deliver equally in 
pharmaceutical and biotech-industry R&D, as well as 
academic research. Proteomics, provides functional 
information concerning the activity of key regulating 
protein target(s) in disease, that the precision medicine 
has been developed for. As a progressive consequence, 
the proteomics impact reflected in the value of the global 
proteomics market has been predictable to have reached 
$17.2, by 2017. (http://www.spectroscopynow.com/
details/news/140df70f7ba/.
Discovering biomarkers that predicts optimal treat-
ment for patients is the holy grail of modern healthcare, 
which relates to the maximized efficacy that personalized 
medicine can provide. Early data, generated from large 
scale studies in lung cancer (non-small cell lung cancer, 
“NSCLC”), was proven to be of mandatory importance 
for predictive treatments of patients in Japan, as well as 
China and Korea [1–3]. These pioneering clinical studies, 
somatic mutation sequencing, complemented by prot-
eomics profiling, later became a standard to Gefitinib 
(Iressa) developed by AstraZeneca. The drug agency, 
MLWH in Japan played an important role in these devel-
opments, requesting additional detailed data that linked 
the treatment of lung cancer patients to optimal efficacy 
and safety.
The introduction of Erlotinib (Tarceva) by Roche, as a 
targeted treatment in Japan followed the same strategy in 
predicative patient responders, as Iressa first outlined in 
Japan. Nowadays an entire range of small molecule drugs 
are available for cancer patients with tyrosine kinase 
inhibition (TKI) properties. GSK introduced Lapatinib, 
as a dual TKI, where HER2 and EGF pathway interrup-
tion occurs. As a consequence to all these developments, 
the MHLW presented a new strategy, where companion 
diagnostics are requested for new drugs that are intro-
duced into the Japanese market. This strategy being 
implemented in Japan is to be expected to be followed as 
a basic healthcare principle worldwide.
These new practices have been complemented by the 
4P medicine concept, introduced by Leroy Hood, (Insti-
tute for Systems Biology in Seattle), where proteomic 
multiplexing assays are included. The most recent 4P 
medicine Obama Healthcare initiated a “Big data” study, 
where 1 million patients will be incorporated with a total 
budget of $225 Mill. President Obama’s Precision Medi-
cine Program with Leroy Hood has paved the way for the 
ability to predict and provide the right medicine to the 
right patient.
As the drug portfolio is increasing with safer and bet-
ter products, national research programs are initiated 
globally to drive new initiatives to promote these devel-
opments. The Global Research Laboratory (GRL) pro-
ject program in Korea is an example of an initiative for 
new technology developments to discover new chemi-
cal compound entities in nature products. Detailed drug 
action mechanisms are developed for medically active 
molecules isolated from plants and natural products [4, 
5]. Understanding the mechanisms of drug action is key, 
in order to optimally design and develop drug molecules 
that provide optimal treatments for patients. It has to 
be emphasized that every new drug, being ordinated for 
a given patient involves a safety risk. These experiences 
have been developed over the last decade, especially in 
Cancer diseases, where some percentage of late stage 
patients will die during the treatment. These mortalities 
are most often associated by a combination of drug side 
effects and a complex pathology status of the patient. 
Imaging technologies by mass spectrometry is a grow-
ing science field, where both biomarkers in a pathological 
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setting and drug mechanisms are being defined. Detailed 
molecular mechanisms and the metabolism of drugs are 
outlined as a part of the documentation requested by the 
authorities. Nowadays, we are able to provide MS imag-
ing data on drug localization from a patient with a resolu-
tion at <10 µm. This resolving power provides data from 
a drug and metabolite, with a quantitative image-map at 
an intracellular organelle level. Mass spectrometry imag-
ing is standard in Big-Pharna, where drug characteristics 
data requested by the FDA are determined. Fehniger and 
Marko-Varga were the first to introduce drug localization 
data in lung cancer-, and COPD- clinical studies, after 
drug administration [6, 7].
HUPO, the global human proteomics community 
enters fully engaged in projects that aim to create a bet-
ter understanding of human biology and its complexities 
and to provide products from this new knowledge that 
will benefit humanity. We are heading towards a future, 
where high-quality standardized biomarkers of health, 
disease, response to therapy into the approval processes 
of regulatory agencies, e.g., U.S. Food and Drug Admin-
istration; FDA, and obtaining approval from the relevant 
agencies for their use in a clinical or other testing set-
tings. To achieve this goal, its clear that the employment 
of standard processes for biobanking human clinical 
samples and enforcement of measures to ensure subject 
integrity, for the downstream use of samples.
It is envisaged that the increasing number of super-
active drugs, such as personalized medicine for targeted 
treatment will foster new technology paradigms in mass 
spectrometry measurement. Proteomics platforms will 
open up new horizons in our understanding of protein 
expression, localization, interaction, structure, and physi-
ological consequences important for patient treatment. 
There is especially an urgent need for a better under-
standing of target protein functions in human health and 
disease. The challenge is to find ways to provide neces-
sary infrastructure and resources in proteomics, espe-
cially at the local level, to all members of the proteomics 
community.
Our proteomics community is actively responding to 
many of the goals and unmet needs of today’s society 
that is also supported by HUPO. We believe that these 
actions will build the foundation for providing solutions 
for meeting future needs. Finally, personalized medi-
cine represents a paradigm shift with drug development 
research and therapy that changes patient treatments on 
a daily basis.
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